Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Amino acid metabolism in breast cancer: pathogenic drivers and therapeutic opportunities

  • Liu, Yawen
  • Zong, Xiangyun
  • Altea-Manzano, Patricia
  • Fu, Jie
Amino acid metabolism plays a critical role in the progression and development of breast cancer. Cancer cells, including those in breast cancer, reprogram amino acid metabolism to meet the demands of rapid proliferation, survival, and immune evasion. This includes alterations in the uptake and utilization of amino acids, such as glutamine, serine, glycine, and arginine, which provide essential building blocks for biosynthesis, energy production, and redox homeostasis. Notably, the metabolic phenotypes of breast cancer cells vary across molecular subtypes and disease stages, emphasizing the need for patient stratification and personalized therapeutic strategies. Advances in multi-level diagnostics, including phenotyping and predictive tools, such as AI-based analysis and body fluid profiling, have highlighted the potential for tailoring treatments to individual metabolic profiles. Enzymes, such as glutaminase and serine hydroxymethyltransferase, often upregulated in breast cancer, represent promising therapeutic targets. Understanding the interplay between amino acid metabolism and breast cancer biology, alongside the integration of personalized medicine approaches, can uncover novel insights into tumor progression and guide the development of precision therapies. This review explores the metabolic pathways of amino acids in breast cancer, with a focus on their implications for personalized treatment strategies., We apologize to the colleagues whose relevant work could not be cited in this review due to space constraints. YL receives funding from the National Natural Science Foundation of China (82403542), Shanghai Pujiang Program (24PJD086) and Fundamental research projects of the hospital level of Shanghai Sixth People’s Hospital (ynqn202424). PA-M acknowledges funding from European Research Council (ERC-StG-101116912), MCIN/AEI/10.13039/501100011033 and European Union (PID2023-152426OA-I00) and Beug Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Palmitoylation-mediated regulation of KAT2A promotes lung metastasis in breast cancer

  • Liu, Ming
  • Vandekeere, Anke
  • Liu, Xiao-Zheng
  • Schenck, Stephan
  • Fernández-García, Juan
  • Tricot, Tine
  • Peng-Winkler, Yiming
  • Demicco, Margherita
  • Broekaert, Dorien
  • Vermeire, Ines
  • Theile, Janine
  • Zels, Gitte
  • Pabba, Anirudh
  • Desmedt, Christine
  • Brunner, Janine D.
  • Altea-Manzano, Patricia
  • Fendt, Sarah-Maria
Acetylation is frequently dysregulated in cancer, and both acetyltransferase and deacetylase inhibitors are being evaluated at various stages of preclinical and clinical development. However, how the expression of acetyltransferases and deacetylases is regulated remains often elusive. We focused on the lysine acetyltransferase 2A (KAT2A) as it is important in multiple cancer indications with a clinical inhibitor in development. We discovered that KAT2A expression is regulated by palmitoylation in breast cancer-derived metastases. Specifically, we find that the palmitoyltransferase DHHC20 (gene name ZDHHC20) palmitoylates transmembrane 4L six family member 1 (TM4SF1) promoting its plasma membrane localization. This in turn fosters phosphorylation of the signal transducer and activator of transcription 3 (STAT3), which we identify as a transcriptional regulator of KAT2A. Accordingly, Zdhhc20 and Tm4sf1 silencing as well as expression of a Tm4sf1 double palmitoylation mutant decreases lung metastasis growth, which is rescued by Kat2a expression. We detect evidence of this palmitoylation-induced regulation of KAT2A in lung metastasis samples from patients with breast cancer. Thus, we show that palmitoylation can orchestrate the expression of a global acetylation regulator in lung metastases., M.L and A.V. have received fellowships from the China Scholarship Council (CSC) and the Research Foundation – Flanders (FWO), respectively. J.F.G. is a previous recipient of Research Foundation–Flanders (FWO) fellowships. X.-Z.L. has been a EMBO postdoctoral fellow (ALTF 401-2022) and has received funding from FWO (1231025N) and Gilead Sciences Research Scholars Program in Solid Tumours and Research Foundation. Y.P.-W. is supported by a Walter-Benjamin fellowship of the German Research Foundation (DFG 521676159). P.A.M. was supported by a Marie Sklodowska-Curie Actions individual fellowship (MSCA-IF-2018-839896) and has received funding from European Union (ERC-StG-101116912) and Beug Foundation. The UPTIDER programme is supported by a grant from the University Hospitals from Leuven (KOOR 2021), as well as a C1 grant (14/21/114) from KU Leuven. S.-M.F. acknowledges funding from FWO project G0B4122N, Fonds Baillet Latour, Francqui Stichting, Foundation ARC, KU Leuven Methusalem funding (METH/26/009), Stichting tegen Kanker (2022-173), Wereld Kanker Onderzoek Fonds, as part of the World Cancer Research Fund International grant programme (IIG_FULL_2023_001) and the Interuniversity BOF programme., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting the Lipid Metabolism Proteins FASN and GPAM in Alveolar Type II Cells Decreases Lung Metastasis

  • Liu, Xiao-Zheng
  • Panina, Yulia
  • Cai, Weigang
  • Fernández-García, Juan
  • Peng-Winkler, Yiming
  • Mao, Jiadong
  • Dahlhaus, Alina
  • Zhou, Hui-Chao
  • Liu, Ming
  • Planque, Mélanie
  • Ceuppens, Johannes
  • Igelmann, Sebastian
  • Spotbeen, Xander
  • Idkowiak, Jakub
  • Dehairs, Jonas
  • Theile, Janine
  • Axarlis, Konstantinos
  • Borremans, Kristien
  • Van Cauwenberge, Josephine
  • Ghanate, Avinash
  • Tarragó-Celada, Josep
  • Suárez-Bonnet, Alejandro
  • Mitter, Richard
  • Wu, Vincen
  • Inglese, Paolo
  • McKenzie, James S.
  • Steven, Rory T.
  • Dexter, Alex
  • Yan, Bin
  • Vorng, Jean-Luc
  • Takáts, Zoltán
  • Bunch, Josephine
  • Gilmore, Ian S.
  • Carmeliet, Peter
  • Desmedt, Christine
  • Malanchi, Ilaria
  • Swinnen, Johannes V.
  • Altea-Manzano, Patricia
  • Lê Cao, Kim-Anh
  • Meiser, Johannes
  • Yuneva, Mariia
  • Fendt, Sarah-Maria
Cancer cells that seed in the lung require lipids often produced by alveolar type II (AT2) cells. However, whether overt metastases depend on AT2 cell-derived lipids and whether AT2 cells can be targeted to reduce metastasis growth remains unknown. We discovered that breast cancer-derived lung metastases stimulate the proliferation of AT2 cells in their vicinity and reprogram them into lipid feeder cells in mice and patients using spatial analysis. Mechanistically, the metastasis secretome activates the transcription factor sterol regulatory element-binding transcription factor 1 (SREBP-1) in AT2 cells, enhancing the expression of key de novo lipid synthesis genes, including fatty acid synthase (FASN) and glycerol-3-phosphate acyltransferase 1 (GPAM). Deleting Fasn selectively in AT2 cells or targeting FASN and GPAM systemically significantly impairs lung metastasis growth in mice. In summary, we discovered that overt metastases reprogram AT2 cells and that targeting the lipid metabolism of AT2 cells impairs metastasis growth., X.-Z. Liu was an EMBO postdoctoral fellow (ALTF 401-2022) and has received funding from FWO (1231025N) and Gilead Sciences Research Scholars Program in Solid Tumors and Research Foundation as well as the Beug Foundation. J. Fernández-García is a previous recipient of Research Foundation – Flanders (FWO) junior/senior postdoctoral fellowships. P. Altea-Manzano was supported by a Marie Sklodowska-Curie Actions individual fellowship (MSCA-IF-2018-839896) and has received funding from European Union (ERC-StG-101116912) and Beug Foundation. Y. Peng-Winkler has received a Walter Benjamin Fellowship from the German Research Foundation (DFG 521676159). J. Mao and K.-A. Lê Cao were supported by the Australian National Health and Medical Research Council (NHMRC) Investigator Grant (GNT2025648). J. Meiser received funding from the European Union (ERC-CoG-101124557) and Luxembourgish research Fund (FNR-CORE C21/BM/15718879). M. Liu has received a fellowship from the Chinese Research Council (CSC). S. Igelmann received funding from EMBO postdoctoral fellow (ALTF 13-2022) and from Research Foundation – Flanders (FWO) junior postdoctoral fellowship (1266225N). J. Van Cauwenberge and K. Borremans were funded by the fund Nadine de Beauffort. The UPTIDER program is supported by a grant from from the Klinische Onderzoeks- en Opleidingsraad (KOOR) of University Hospitals Leuven (Uitzonderlijke Financiering 2020), by C1 of KU Leuven (C14/21/114), by the Belgian Cancer Foundation (grant number: C/2022/2046), by the Research Foundation Flanders (FWO, grant number: G082524N) and by the Breast Cancer Research Foundation (BCRF, grant number: BCRF-24-212). M. Yuneva, Z. Takáts and J. Bunch acknowledge funding from the CRUK Grand Challenge Award 2015 C57633/A25043. M. Yuneva acknowledges funding from the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001223), the UK Medical Research Council (FC001223), and the Wellcome Trust (FC001223, FC0010060). S.-M. Fendt acknowledges funding from FWO Projects, Fonds Baillet Latour, Francqui Stichting, Foundation ARC, KU Leuven C1, Small Equipment and Methusalem programs (METH/26/009), Stichting tegen Kanker (2022-173 and 2022-034), and Wereld Kanker Onderzoek Fonds (WKOF), as part of the World Cancer Research Fund International grant program (IIG_FULL_2023_001) and the Interuniversity BOF (iBOF) program., Peer reviewed